Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Breast cancer vaccine study

09.02.2004


Study evaluates immune response to telomerase tumor antigen as possible vaccine



Researchers at the Abramson Cancer Center of the University of Pennsylvania have begun a Phase I clinical trial to evaluate the effectiveness of a telomerase peptide as a possible vaccine against breast cancer. The study will measure potential tumor cell shrinkage in patients after an immune response has been triggered to an antigen – the telomerase peptide – found in more than 90 percent of breast cancer tumors.

The study is made possible through a unique $500,000 grant from the "Avon-NCI Progress for Patients" Awards program, a special private-public partnership between the Avon Foundation, Inc. and the National Cancer Institute (NCI) dedicated to accelerating early phase clinical research into promising therapies.


"This is the first clinical study to use a telomerase peptide as a possible vaccine against breast cancer," said lead researcher Robert Vonderheide, MD, DPhil, an assistant professor at the Leonard and Madlyn Abramson Family Cancer Research Institute at the University of Pennsylvania. "Our hope is that the immune response will kill the cancer and improve the health of patients."

Twenty-eight patients with metastatic breast cancer will be enrolled in the study, which is expected to last two years. Patients will be injected with one of three escalating doses of the telomerase antigen in combination with adjuvant therapies (granulocyte-macrophage colony stimulating factor, GM-CSF) over a period of seven months. The immune and tumor response to the telomerase-based vaccine will be monitored over the duration of the study and compared to a control response to an injection of cytomegalovirus peptide.

Avon/NCI-Funded Breast Cancer Vaccine Trial…

The results of an earlier feasibility study – also led by Vonderheide and published in the February 1st edition of the journal Clinical Cancer Research – showed immune responses with little toxicity in seven breast and prostate cancer patients after they were injected with small amounts of a similar telomerase peptide vaccine.

"One breast cancer patient in the earlier study showed temporary tumor regression, prompting us to accelerate research into the possibility of a vaccine," said trial principal investigator Susan Domchek, MD, a breast medical oncologist at the Abramson Cancer Center and assistant professor at Penn’s School of Medicine.

Patients can obtain further information about the trial by calling: 215-615-3360, or toll free at 1-800-789-Penn (7366).


About the Abramson Cancer Center:

The Abramson Cancer Center of the University of Pennsylvania was established in 1973 as a center of excellence in cancer research, patient care, education and outreach. Today, the Abramson Cancer Center ranks as one of the nation’s best in cancer care, according to US News and World Report, and is one of the top five in National Cancer Institute (NCI) funding. It is one of only 39 NCI-designated comprehensive cancer centers in the United States. Home to one of the largest clinical and research programs in the world, the Abramson Cancer Center of the University of Pennsylvania has 275 active cancer researchers and 250 Penn physicians involved in cancer prevention, diagnosis and treatment.

David March | EurekAlert!
Further information:
http://www.uphs.upenn.edu/news
http://www.pennhealth.com/cancer

More articles from Studies and Analyses:

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

nachricht First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>